COMMUNIQUÉS West-GlobeNewswire

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
10/11/2025
Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; [...]
Health Catalyst Reports Third Quarter 2025 Results
10/11/2025
SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
Completed the sale of FibroGen China to AstraZeneca for approximately $220 million Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in [...]
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
10/11/2025
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean [...]
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
10/11/2025
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B- [...]
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
10/11/2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases [...]
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control [...]
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data from the HOPE-3 [...]
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
10/11/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON, [...]
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
10/11/2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has [...]
MIMEDX to Participate in Upcoming Investor Conferences
10/11/2025
MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
10/11/2025
Fireside chat scheduled for Wednesday November 12, 2025 at 10:00 AM ET NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and [...]
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
10/11/2025
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy [...]
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
10/11/2025
COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94 [...]
Regional Health Properties, Inc. Reports Sale of Skilled Nursing Facility
10/11/2025
Atlanta, GA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional,” the “Company,” “we,” “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB: RHEPZ) today announced the completion [...]
NeXtGen Biologics and Lovell® Government Services Partner to Bring Innovative Advanced Wound Care Technology to Federal Healthcare Systems
10/11/2025
PENSACOLA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lovell ® Government Services and NeXtGen™ Biologics, Inc., a medical device company that manufactures NeoMatriX ® , announced today that they have partnered to serve [...]
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
10/11/2025
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated [...]
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
10/11/2025
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
10/11/2025
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel [...]

Pages